Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

231 recalls · Class I, newest first

Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0181-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0180-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0179-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablet

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0178-2025
Class I · High risk

ZapMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0086-2025
Class I · High risk

ZoomMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0085-2025
Class I · High risk

PeakMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0084-2025
Class I · High risk

VitalityXtra Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0083-2025
Class I · High risk

Umary Acido Hialuronico

Marketed without Approved NDA/ANDA. FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.

Ongoing Chemical / undeclared Main Products INC D-0626-2024
Class I · High risk

Umary Acido Hialuronico

Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.

Ongoing Chemical / undeclared SoloVital D-0620-2024
Class I · High risk

Gold Hard Steel Plus Liquid

Marketed without an approved NDA/ANDA: FDA analysis found products to be tainted with undeclared acetaminophen and sildenafil.

Ongoing Chemical / undeclared Supercore Products Group Inc. D-0004-2025
Class I · High risk

Healthy Living Acetaminophen

Labeling: Missing Label - some bottles are missing the the manufacturers label that includes the drug facts information.

Ongoing Labeling / mix-up Aurobindo Pharma USA Inc NDC 58602-882-21 D-0641-2024
Class I · High risk

Acetaminophen Injection

Labeling: Label Mix-up: a bag of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection was found inside an overwrap labeled Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL)

Ongoing Labeling / mix-up Hikma Pharmaceuticals USA Inc. NDC 0143-9386-01 D-0635-2024
Class I · High risk

Docetaxel Injection

Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.

Ongoing Particulate / foreign matter Sagent Pharmaceuticals NDC 25021-254-08 D-0554-2024
Class I · High risk

Docetaxel Injection

Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.

Ongoing Particulate / foreign matter Sagent Pharmaceuticals NDC 25021-254-08 D-0553-2024

Recalls by year